EP 1063996 A1 20010103 - PHARMACEUTICAL COMPOSITIONS CONTAINING IN COMBINATION TWO ANTAGONISTS SELECTIVE OF ARGININE-VASSOPRESSIN V RECEPTORS, EVEN OF V 1A? AND V 2? RECEPTORS
Title (en)
PHARMACEUTICAL COMPOSITIONS CONTAINING IN COMBINATION TWO ANTAGONISTS SELECTIVE OF ARGININE-VASSOPRESSIN V RECEPTORS, EVEN OF V 1A? AND V 2? RECEPTORS
Title (de)
ARZNEIMITTEL MIT ZWEI SELEKTIVEN HEMMERN DER ARGININ-VASOPRESSIN-V-REZEPTOREN, NÄMLICH DER REZEPTOREN V-1A UND V-2
Title (fr)
COMPOSITIONS PHARMACEUTIQUES CONTENANT EN ASSOCIATION DEUX ANTAGONISTES SELECTIFS DES RECEPTEURS V DE L'ARGININE-VASOPRESSINE, VOIR DES RECEPTEURS V-1A ET V-2
Publication
Application
Priority
- FR 9900450 W 19990301
- FR 9802874 A 19980306
Abstract (en)
[origin: FR2775598A1] The invention concerns pharmaceutical compositions containing in combination (2S)- 1-[(2R,3S)- 5-chloro-3-(2-chlorophenyl)-1- (3, 4-dimethoxybenzenesulphonyl)-3-hydroxy-2, 3-dihydro-1H-indole-2- (carbonyl]pyrrolidine-2-carboxamide, antagonist selective of V1a arginine-vasopressin receptors, with 1- [4-(N-tert-butylcarbamoyl)-2- methoxybenzenesulphonyl]-5-ethoxy-3-spiro[4- (2-morpholinoethyloxy)cyclohexane]indol-2-one, the equatorial isomer, or one of the salts thereof, antagonist selective of V2 arginine-vasopressin. The invention also concerns the use of said compositions for preparing medicines for treating all pathologies in which either arginine-vasopressin, or V2 receptors are involved.
IPC 1-7
IPC 8 full level
A61K 31/403 (2006.01); A61K 31/404 (2006.01); A61K 31/535 (2006.01); A61K 31/5377 (2006.01); A61P 1/00 (2006.01); A61P 5/00 (2006.01); A61P 7/10 (2006.01); A61P 9/00 (2006.01); A61P 11/00 (2006.01); A61P 13/12 (2006.01); A61P 15/10 (2006.01); A61P 25/00 (2006.01); A61P 27/02 (2006.01); A61P 27/06 (2006.01); A61P 43/00 (2006.01); C07D 209/96 (2006.01); C07D 403/06 (2006.01)
CPC (source: EP US)
A61K 31/535 (2013.01 - EP US); A61P 1/00 (2017.12 - EP); A61P 5/00 (2017.12 - EP); A61P 7/10 (2017.12 - EP); A61P 9/00 (2017.12 - EP); A61P 11/00 (2017.12 - EP); A61P 13/12 (2017.12 - EP); A61P 15/10 (2017.12 - EP); A61P 25/00 (2017.12 - EP); A61P 27/02 (2017.12 - EP); A61P 27/06 (2017.12 - EP); A61P 43/00 (2017.12 - EP)
Citation (search report)
See references of WO 9944613A1
Designated contracting state (EPC)
AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE
DOCDB simple family (publication)
FR 2775598 A1 19990910; AR 016984 A1 20010801; AU 2629299 A 19990920; CO 5070635 A1 20010828; EP 1063996 A1 20010103; GT 199900027 A 20000819; JP 2002505289 A 20020219; US 6627649 B1 20030930; WO 9944613 A1 19990910; ZA 991765 B 19990906
DOCDB simple family (application)
FR 9802874 A 19980306; AR P990100923 A 19990304; AU 2629299 A 19990301; CO 99013704 A 19990305; EP 99906313 A 19990301; FR 9900450 W 19990301; GT 199900027 A 19990226; JP 2000534215 A 19990301; US 62277800 A 20001006; ZA 991765 A 19990304